Abstract:Introduction: Parkinson’s disease (PD) is characterized by fibrillation of disordered proteins known as Lewy bodies in the substantia nigra that also undergo progressive neurodegeneration. The aggregation of α-synuclein (α-syn) is a hallmark and potentially a critical step in the development of Parkinson’s disease and other synucleinopathies. The synaptic vesicle protein α-syn is a small, abundant, highly conserved disordered protein and the causative agent of neurodegenerative diseases. Several novel pharmacologically active compounds are used to treat PD and other neurodegenerative disorders. Though, the mechanism through which these molecules inhibit the α-syn aggregation is still not fully understood. Objective: This review article is focused on the recent advancements in compounds that can inhibit the development of α-syn fibrillation and oligomerization. Methods: The current review article is based on the most recent and frequently cited papers from Google Scholar, SciFinder, and Researchgate sources. Description: In the progression of PD, the mechanism of α-syn aggregation involves the structural transformation from monomers into amyloid fibrils. As the accumulation of α-syn in the brain has been linked to many disorders, the recent search for disease-modifying medications mainly focused on modifying the α-syn aggregation. This review contains a detailed report of literature findings and illustrates the unique structural features, structure-activity relationship, and therapeutic potential of the natural flavonoids in the inhibition of α-syn are also discussed. Conclusion: Recently, many naturally occurring molecules such as curcumin, polyphenols, nicotine, EGCG, and stilbene have been recognized to inhibit the fibrillation and toxicity of α-syn. Therefore, knowing the α-synuclein filament's structure and how they originate will help invent particular biomarkers for synucleinopathies and develop reliable and effective mechanism-based therapeutics. We hope the information this review provides may help evaluate novel chemical compounds, such as α- syn aggregation inhibitors, and will contribute to developing novel drugs for treating Parkinson’s disease.

Understanding the Modulation of α-Synuclein Fibrillation by N -Acetyl Aspartate: A Brain Metabolite

Analysis of a Single Α-Synuclein Fibrillation by the Interaction with a Protein Nanopore.

Coupling of the Non-Amyloid-component (NAC) Domain and the KTK(E/Q)GV Repeats Stabilize the Α-Synuclein Fibrils.

A targetable N-terminal motif orchestrates α-Synuclein oligomer to fibril conversion

Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis

The influence of N-terminal acetylation on micelle-induced conformational changes and aggregation of α-Synuclein

Structural packing of the non-amyloid component core domain in α-synuclein plays a role in the stability of the fibrils

Novel Mannitol-Based Small Molecules for Inhibiting Aggregation of Α-Synuclein Amyloids in Parkinson's Disease

Alpha-synuclein phosphorylation induces amyloid conversion via enhanced electrostatic bridging: Insights from molecular modeling of the full-length protein

Catechol‐induced covalent modifications modulate the aggregation tendency of α‐synuclein: An in‐solution and in‐silico study

Research Progress of Α-Synuclein Aggregation Inhibitors for Potential Parkinson’s Disease Treatment

A Targetable N-Terminal Motif Orchestrates α-Synuclein Oligomer-to-Fibril Conversion

The intracellular milieu of Parkinson’s disease patient brain cells modulates alpha-synuclein protein aggregation

Molecular Insights into the Misfolding and Dimerization Dynamics of the Full-Length Α-Synuclein from Atomistic Discrete Molecular Dynamics Simulations.

Exploring α-synuclein stability under the external electrostatic fields: Effect of repeat unit

Modulation Effects of Fe3+, Zn2+, and Cu2+ Ions on the Amyloid Fibrillation of Α-Synuclein: Insights from a FTIR Investigation.

Conformation-specific Binding of α-Synuclein to Novel Protein Partners Detected by Phage Display and NMR Spectroscopy

Trehalose Inhibits Fibrillation of A53T Mutant Alpha-Synuclein and Disaggregates Existing Fibrils

N-Terminal Acetylation Preserves Α-Synuclein from Oligomerization by Blocking Intermolecular Hydrogen Bonds.

Selection of DNA aptamers that prevent the fibrillization of α-synuclein protein in cellular and mouse models

Inhibition of Α‐synuclein Fibrillization by Dopamine Analogs Via Reaction with the Amino Groups of Α‐synuclein